- Report
- June 2026
- 100 Pages
United States
From €4250EUR$4,750USD£3,635GBP
- Report
- June 2025
- 607 Pages
Global
From €4294EUR$4,799USD£3,672GBP
- Report
- January 2025
- 363 Pages
Global
From €4294EUR$4,799USD£3,672GBP
- Report
- September 2024
- 375 Pages
Global
From €4294EUR$4,799USD£3,672GBP
- Report
- April 2019
- 850 Pages
Global
From €4026EUR$4,499USD£3,442GBP
- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,394USD£1,770GBP
- Report
- August 2026
Global
From €450EUR$539USD£398GBP
- Report
- August 2026
Global
From €750EUR$898USD£664GBP
- Report
- August 2026
Global
From €600EUR$718USD£531GBP
- Report
- August 2026
Global
From €300EUR$359USD£266GBP
- Report
- August 2026
Global
From €300EUR$359USD£266GBP
- Report
- August 2026
Global
From €200EUR$239USD£177GBP
- Report
- March 2025
- 84 Pages
Global
From €400EUR$479USD£354GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,574USD£1,903GBP
- Report
- June 2022
- 115 Pages
Global
From €1050EUR$1,257USD£929GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$599USD£443GBP
- Report
- May 2022
- 32 Pages
Global
From €400EUR$479USD£354GBP
- Report
- December 2023
- 307 Pages
Global
From €4429EUR$4,950USD£3,788GBP
- Report
- March 2025
- 1048 Pages
Global
From €4294EUR$4,799USD£3,672GBP
- Report
- August 2025
- 1300 Pages
Global
From €3758EUR$4,200USD£3,214GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more